Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 3;3(3):CD012040.
doi: 10.1002/14651858.CD012040.pub3.

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis

Aisha A Aslam  1 , Ian P Sinha  2 , Kevin W Southern  2
Affiliations

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis

Aisha A Aslam et al. Cochrane Database Syst Rev. .

Abstract

Background: Cystic fibrosis (CF) is a common, life-shortening, genetic disorder in populations of Northern European descent caused by the mutation of a single gene that codes for the production of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This protein coordinates the transport of salt (and bicarbonate) across cell surfaces, and the mutation most notably affects the airways. In the lungs of people with CF, the defective protein compromises mucociliary clearance and makes the airway prone to chronic infection and inflammation, damaging the structure of the airways and eventually leading to respiratory failure. In addition, abnormalities in the truncated CFTR protein lead to other systemic complications, including malnutrition, diabetes and subfertility. Five classes of mutation have been described, depending on the impact of the mutation on the processing of the CFTR protein in the cell. In class I mutations, premature termination codons prevent the production of any functional protein, resulting in severe CF. Therapies targeting class I mutations aim to enable the normal cellular mechanism to read through the mutation, potentially restoring the production of the CFTR protein. This could, in turn, normalise salt transport in the cells and decrease the chronic infection and inflammation that characterises lung disease in people with CF. This is an update of a previously published review.

Objectives: To evaluate the benefits and harms of ataluren and similar compounds on clinically important outcomes in people with CF with class I mutations (premature termination codons).

Search methods: We searched the Cochrane Cystic Fibrosis Trials Register, which is compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the reference lists of relevant articles. The last search of the Cochrane Cystic Fibrosis Trials Register was conducted on 7 March 2022. We searched clinical trial registries maintained by the European Medicines Agency, the US National Institutes of Health and the World Health Organization. The last search of the clinical trials registries was conducted on 4 October 2022.

Selection criteria: Randomised controlled trials (RCTs) of parallel design comparing ataluren and similar compounds (specific therapies for class I mutations) with placebo in people with CF who have at least one class I mutation.

Data collection and analysis: For the included trials, the review authors independently extracted data, assessed the risk of bias and evaluated the certainty of the evidence using GRADE; trial authors were contacted for additional data.

Main results: Our searches identified 56 references to 20 trials; of these, 18 trials were excluded. Both the included parallel RCTs compared ataluren to placebo for 48 weeks in 517 participants (males and females; age range six to 53 years) with CF who had at least one nonsense mutation (a type of class I mutation). The certainty of evidence and risk of bias assessments for the trials were moderate overall. Random sequence generation, allocation concealment and blinding of trial personnel were well documented; participant blinding was less clear. Some participant data were excluded from the analysis in one trial that also had a high risk of bias for selective outcome reporting. PTC Therapeutics Incorporated sponsored both trials with grant support from the Cystic Fibrosis Foundation, the US Food and Drug Administration's Office of Orphan Products Development and the National Institutes of Health. The trials reported no difference between treatment groups in terms of quality of life, and no improvement in respiratory function measures. Ataluren was associated with a higher rate of episodes of renal impairment (risk ratio 12.81, 95% confidence interval 2.46 to 66.65; P = 0.002; I2 = 0%; 2 trials, 517 participants). The trials reported no treatment effect for ataluren for the review's secondary outcomes of pulmonary exacerbation, computed tomography score, weight, body mass index and sweat chloride. No deaths were reported in the trials. The earlier trial performed a post hoc subgroup analysis of participants not receiving concomitant chronic inhaled tobramycin (n = 146). This analysis demonstrated favourable results for ataluren (n = 72) for the relative change in forced expiratory volume in one second (FEV1) per cent (%) predicted and pulmonary exacerbation rate. The later trial aimed to prospectively assess the efficacy of ataluren in participants not concomitantly receiving inhaled aminoglycosides, and found no difference between ataluren and placebo in FEV1 % predicted and pulmonary exacerbation rate. AUTHORS' CONCLUSIONS: There is currently insufficient evidence to determine the effect of ataluren as a therapy for people with CF with class I mutations. One trial reported favourable results for ataluren in a post hoc subgroup analysis of participants not receiving chronic inhaled aminoglycosides, but these were not reproduced in the later trial, suggesting that the earlier results may have occurred by chance. Future trials should carefully assess for adverse events, notably renal impairment, and consider the possibility of drug interactions. Cross-over trials should be avoided, given the potential for the treatment to change the natural history of CF.

Trial registration: ClinicalTrials.gov NCT00803205 NCT02139306 NCT02107859.

PubMed Disclaimer

Conflict of interest statement

AA declares no potential conflict of interest.

IS declares no potential conflict of interest.

KS declares no potential conflict of interest.

Figures

1
1
PRISMA study flow diagram
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Ataluren versus placebo, Outcome 1: QoL score (measured using CFQ‐R) ‐ change from baseline
1.2
1.2. Analysis
Comparison 1: Ataluren versus placebo, Outcome 2: FEV1 % predicted ‐ mean relative change from baseline
1.3
1.3. Analysis
Comparison 1: Ataluren versus placebo, Outcome 3: FEV1 % predicted ‐ mean relative change from baseline: subgroup analysis of participants not receiving chronic inhaled tobramycin
1.4
1.4. Analysis
Comparison 1: Ataluren versus placebo, Outcome 4:  FEV1 % predicted ‐ mean relative change from baseline: subgroup analysis of participants receiving chronic inhaled tobramycin
1.5
1.5. Analysis
Comparison 1: Ataluren versus placebo, Outcome 5: FEV1 % predicted ‐ mean absolute change from baseline
1.6
1.6. Analysis
Comparison 1: Ataluren versus placebo, Outcome 6: FEV1 % predicted ‐ mean absolute change from baseline: subgroup of participants not receiving chronic inhaled tobramycin
1.7
1.7. Analysis
Comparison 1: Ataluren versus placebo, Outcome 7: FVC % predicted ‐ mean relative change from baseline
1.8
1.8. Analysis
Comparison 1: Ataluren versus placebo, Outcome 8: Specific adverse events (at up to 48 weeks)
1.9
1.9. Analysis
Comparison 1: Ataluren versus placebo, Outcome 9: Severity of adverse effects of therapy as graded by trial authors
1.10
1.10. Analysis
Comparison 1: Ataluren versus placebo, Outcome 10: Pulmonary exacerbation rate
1.11
1.11. Analysis
Comparison 1: Ataluren versus placebo, Outcome 11: Protocol‐defined pulmonary exacerbation rate: subgroup analysis by chronic inhaled tobramycin use
1.12
1.12. Analysis
Comparison 1: Ataluren versus placebo, Outcome 12: Total lung computed tomography score ‐ mean change from baseline
1.13
1.13. Analysis
Comparison 1: Ataluren versus placebo, Outcome 13: Body mass index ‐ change from baseline
1.14
1.14. Analysis
Comparison 1: Ataluren versus placebo, Outcome 14: Sweat chloride level ‐ change from baseline
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Kerem 2014 {published data only}
    1. Ajayi T, Konstan M, Accurso FJ, De Boeck K, Kerem E, Rowe S, et al. The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease. Journal of Cystic Fibrosis 2013;12(Suppl 1):S64. [ABSTRACT NO.: 63] [CENTRAL: 921666] [CFGD REGISTER: BD167h]
    1. Davies JC, Tiddens HA, Malfroot A, Heijerman HG, Kerem E, Hjelte L, et al. Ataluren in nonsense mutation cystic fibrosis patients not receiving tobramycin: significant lung function benefits in the paediatric age range. Journal of Cystic Fibrosis 2016;15(Suppl 1):S21. [ABSTRACT NO.: WS13.11] [CENTRAL: 1171482] [CFGD REGISTER: BD167q]
    1. De Boeck C, Heijerman H, Davies JC, Sermet-Gaudelus I, Hjelte L, Kerem E, et al. Clinical benefits of ataluren in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled tobramycin. Pediatric Pulmonology 2016;51(S45):273. [CENTRAL: CN-01475146] [CFGD REGISTER: BD167u] [EMBASE: 612359309]
    1. De Boeck K, Heijerman HG, Davies JC, Sermet-Gaudelus I, Hjelte L, Kerem E, et al. Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin. Journal of Cystic Fibrosis 2016;15(Suppl 1):S20. [ABSTRACT NO.: WS13.1] [CENTRAL: 1171483] [CFGD REGISTER: BD167p]
    1. DeBoeck K, Sermet-Gaudelus I, Kerem E, Wilschanski M, Accurso FJ, Konstan M, et al. Design of the ataluren confirmatory phase 3, randomised, double-blind, placebo-controlled trial in patients with nonsense mutation cystic fibrosis (ACT CF). Pediatric Pulmonology 2014;49(Suppl 38):312. [ABSTRACT NO.: 269] [CENTRAL: 1012387] [CFGD REGISTER: BD167m]
Konstan 2020 {published data only}
    1. EUCTR2013-004581-34-DE. Confirmatory study of ataluren in patients with Cystic Fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004581-34-DE (date first received 5 August 2014). [CFGD REGISTER: BD239e]
    1. Konstan MW, DiMango E, Kerem E, Melotti P, Rowe S, Sermet-Gaudelus I, et al. Efficacy and safety of ataluren in patients with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in cystic fibrosis (ACT CF). Journal of Cystic Fibrosis 2017;16 (Suppl 1):S23-4. [ABSTRACT NO.: WS13.3] [CFGD REGISTER: BD239a] - PMC - PubMed
    1. Konstan MW, VanDevanter DR, Rowe SM, Wilschanski M, Kerem E, Sermet-Gaudelus I, et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis 2020;19(4):595-601. [CENTRAL: CN-02076266] [CFGD REGISTER: BD239c] [DOI: 10.1016/j.jcf.2020.01.007] [EMBASE: 2004694098] [PMID: ] - DOI - PMC - PubMed
    1. McIntosh J, VanDevanter DR. Comparisons of the original, expanded, and modified Fuchs exacerbation definitions in assessing ataluren-associated exacerbation benefits in cystic fibrosis patients with a CFTR nonsense mutation not receiving chronic inhaled aminoglycoside therapy. Pediatric Pulmonology 2016;51(Suppl 45):280. [CFGD REGISTER: BD239b]
    1. NCT02139306. A phase 3 efficacy and safety study of ataluren (PTC124®) in patients with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02139306 (first received 15 May 2014). [CFGD REGISTER: BD239d]

References to studies excluded from this review

Kerem 2008 {published data only}
    1. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial. Lancet 2008;372:719-27. - PubMed
    1. Kerem E, Yaakov Y, Armoni S, Pugatsch T, Shoseyov D, Cohen M, et al. PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis. Pediatric Pulmonology 2008;43(Suppl 31):294. [CENTRAL: 691199] [CFGD REGISTER: BD203b]
    1. Wilschanski M, Armoni S, Yaakov Y, Blau H, Shoseyov D, Cohen M, et al. PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis 2008;7(Suppl 2):S22. [CENTRAL: 651985] [CFGD REGISTER: BD203a]
    1. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. European Respiratory Journal 2011;38:59-69. - PubMed
NCT00234663 {published data only}
    1. NCT00234663. A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00234663 (first received 7 October 2005).
NCT00237380 {published data only}
    1. NCT00237380. Safety and efficacy of ataluren (PTC124) for cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00237380 (first received 12 October 2005).
NCT00351078 {unpublished data only}
    1. NCT00351078. A phase 2b extension study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00351078 (first received 12 July 2006).
NCT00376428 {unpublished data only}
    1. NCT00376428. Application of functional electrophysiological tests to evaluate pharmacological treatments in patients with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00376428 (first received 14 September 2006).
NCT01140451 {published data only}
    1. NCT01140451. A phase 3 extension study of ataluren (PTC124®) in subjects with nonsense-mutation-mediated cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01140451 (first received 19 October 2020).
NCT02107859 {published data only}
    1. NCT02107859. An open-label safety and efficacy study for patients with nonsense mutation cystic fibrosis previously treated with ataluren (PTC124®). clinicaltrials.gov/ct2/show/NCT02107859 (first received 8 April 2014). [CLINICALTRIALS.GOV: NCT02107859]
NCT02456103 {published data only}
    1. NCT02456103. Extension study of ataluren in participants with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT02456103 (first received 15 April 2020).
NCT03256799 {unpublished data only}
    1. NCT03256799. An open label study to investigate the role of ivacaftor for the treatment of cystic fibrosis in combination with ataluren (PTC124) in cystic fibrosis patients using ataluren for nonsense mutations. clinicaltrials.gov/ct2/show/NCT03256799 (first received 19 July 2019).
NCT03256968 {unpublished data only}
    1. NCT03256968. An open label N of 1 study to evaluate the study and efficacy of long-term treatment with ivacaftor in combination with ataluren (PTC124) in subjects with nonsense mutation cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03256968 (first received 26 March 2020).
NCT03624101 {unpublished data only}
    1. NCT03624101. Novel therapeutic approaches for treatment of CF patients with W1282X premature termination codon mutations. clinicaltrials.gov/ct2/show/NCT03624101 (first received 9 August 2019).
NCT03670472 {unpublished data only}
    1. NCT03670472. Optimization of correcting molecules of nonsense mutations in epithelial cells of the upper airways of patients with cystic fibrosis with nonsense mutations in the CFTR gene. clinicaltrials.gov/ct2/show/NCT03670472 (first received 13 September 2018).
NCT04126473 {unpublished data only}
    1. NCT04126473. A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele. clinicaltrials.gov/ct2/show/NCT04126473 (first received 15 October 2019).
NCT04135495 {unpublished data only}
    1. NCT04135495. A phase 2 open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple dose levels of subcutaneously administered ELX-02 in patients with cystic fibrosis with at least one G542X allele. clinicaltrials.gov/ct2/show/NCT04135495 (first received 22 October 2019).
Pradal 2002 {published data only}
    1. Pradal U, Casotti V, Delmarco A, Nicolis E, Livraghi A, Conese M, et al. Effects of gentamicin on ion transport, mRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study. Pediatric Pulmonology 2002;34, Issue S24:263. [CENTRAL: 404061] [CFGD REGISTER: BD145]
Romano 2000 {published data only}
    1. Romano L, Casciaro R, Vanini P, Zegarra-Moran O, Negro I, Minuto N, et al. Reduction of sweat ion concentrations following topical application of gentamicin in CF patients carrying nonsense mutations. In: 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:11. [CENTRAL: 354451] [CFGD REGISTER: BD144b]
    1. Romano L, Sacchi R, Zegarra-Moran O, Vanini P, Guerriero F, Casciaro R, et al. Effects of topical applications of gentamicin on sweat test in CF patients carrying nonsense-mutations. Pediatric Pulmonology 2000;30, Issue S20:250. [CENTRAL: 315387] [CFGD REGISTER: BD144a]
Sermet‐Gaudelus 2010 {published data only}
    1. EUCTR2007-000724-40-BE. A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007-000724-40-BE (first received 27 April 2007). [CFGD REGISTER: BD22e]
    1. NCT00458341. A study of ataluren in pediatric participants with cystic fibrosis [A phase 2 study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis]. clinicaltrials.gov/show/NCT00458341 (first received 10 April 2007). [CENTRAL: CN-02015168] [CFGD REGISTER: BD22d]
    1. Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2010;182(10):1262-72. [CENTRAL: 768705] [CFGD REGISTER: BD22c] - PubMed
    1. Sermet-Gaudelus I, De Boeck K, Casimir G, Leal T, Vermeulen F, Mogenet A, et al. Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124. Pediatric Pulmonology 2008;43(Suppl 31):313. [CENTRAL: 689497] [CFGD REGISTER: BD22b]
    1. Sermet-Gaudelus I, Leal T, De Boeck K, Casimir G, Hanssens L, Hage P, et al. PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis 2008;7(Suppl 2):S22. [CENTRAL: 651984] [CFGD REGISTER: BD22a]
Wilschanski 2003b {published data only}
    1. Wilschanski M, Virgilis D, Strauss-Liviatan N, Tal A, Bentur L, Blau H, et al. Gentamicin causes functional expression of CFTR in CF patients carrying stop mutations: A double-blind placebo controlled trial. Pediatric Pulmonology 2000;30, Issue S20:244. [CENTRAL: 315400] [CFGD REGISTER: BD143a]
    1. Wilschanski M, Yahav J, Blau H, Bentur L, Rivlin J, Aviram M, et al. Restoration of CFTR function by gentamicin in cystic fibrosis patients carrying stop mutations: A double blind placebo controlled trial. Gastroenterology 2003;124(4 Suppl 1):A582. [CENTRAL: 643127] [CFGD REGISTER: BD143c]
    1. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New England Journal of Medicine 2003;349(15):1433-41. [CENTRAL: 440623] [CFGD REGISTER: BD143b] [PMID: ] - PubMed

Additional references

Boucher 2007
    1. Boucher RC. Cystic fibrosis: A disease of vulnerability to airway surface dehydration. Trends in Molecular Medicine 2007;13(6):231–40. - PubMed
CFMD 2011
    1. Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto, Canada. Cystic fibrosis mutation database. www.genet.sickkids.on.ca/StatisticsPage.html (accessed 15 March 2015).
Clancy 2001
    1. Clancy JP, Bebök Z, Ruiz F, King C, Jones J, Walker L, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2001;163(7):1683-92. - PubMed
Davis 2006
    1. Davis PB. Cystic fibrosis since 1938. American Journal of Respiratory and Critical Care Medicine 2006;173(5):475-82. - PubMed
Deeks 2019
    1. Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Farrell 2018
    1. Farrell P, Férec C, Macek M, Frischer T, Renner S, Riss K, et al. Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. European Journal of Human Genetics 2018;26(12):1832-9. [DOI: 10.1038/s41431-018-0234-z] - DOI - PMC - PubMed
Friedman 2014
    1. Friedman Y. Building Biotechnology. 4th edition. Washington DC: Logo Press, 2014.
Fuchs 1994
    1. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine 1994;331:637-42. [DOI: 10.1056/NEJM199409083311003] - DOI - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2017
    1. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.
Higgins 2022
    1. Higgins JP, Eldridge S, Li T, editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
Howard 1996
    1. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine 1996;2(4):467-9. - PubMed
Kerem 1997
    1. Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genetic Testing 1997;1(1):35-9. - PubMed
McElroy 2013
    1. McElroy SP, Nomura T, Torrie LS, Warbrick E, Gartner U, Wood G, et al. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biology 2013;11(6):1-8. - PMC - PubMed
McKone 2006
    1. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006;130(5):1441-7. - PubMed
Nicholson 2010
    1. Nicholson P, Mühlemann O. Cutting the nonsense: the degradation of PTC-containing mRNAs. Biochemical Society Transactions 2010;38(6):1615-20. [DOI: 10.1042/BST0381615] - DOI - PubMed
Quittner 2009
    1. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8. [DOI: 10.1378/chest.08-1190] - DOI - PMC - PubMed
Skilton 2019
    1. Skilton M, Krishan A, Patel S, Sinha IP, Southern KW. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No: CD009841. [DOI: 10.1002/14651858.CD009841.pub3] - DOI - PMC - PubMed
Southern 2020
    1. Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database of Systematic Reviews 2020, Issue 12. Art. No: CD010966. [DOI: 10.1002/14651858.CD010966.pub3] - DOI - PMC - PubMed
UK CF Trust 2014
    1. CF Trust UK. Cystic fibrosis our focus. UK cystic fibrosis registry annual data report 2013. www.cysticfibrosis.org.uk/sites/default/files/2020-12/2014%20Registry%20... (accessed 15 March 2015).
Welch 2007
    1. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447(7140):87-91. - PubMed
Welsh 2001
    1. Welsh MJ, Ramsey BW, Accurso F, Cutting G. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors(s). The Metabolic and Molecular Basis of Inherited Diseases. 8th edition. New York: McGraw-Hill, 2001:5121–88.
Wilschanski 2003a
    1. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, et al. Gentamicin induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New England Journal of Medicine 2003;349(15):1433-41. - PubMed

References to other published versions of this review

Aslam 2017
    1. Aslam AA, Higgins C, Sinha IP, Southern KW. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No: CD012040. [DOI: 10.1002/14651858.CD012040.pub2] - DOI - PMC - PubMed

Publication types

Associated data